title: A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial.
abstract: BACKGROUND
  Artemisinin-based combination therapies (ACTs) are the mainstay for the management of uncomplicated malaria cases. However, up-to-date data able to assist sub-Saharan African countries formulating appropriate antimalarial drug policies are scarce.
  
  
  RESULTS
  Between 9 July 2007 and 19 June 2009, a randomized, non-inferiority (10% difference threshold in efficacy at day 28) clinical trial was carried out at 12 sites in seven sub-Saharan African countries. Each site compared three of four ACTs, namely amodiaquine-artesunate (ASAQ), dihydroartemisinin-piperaquine (DHAPQ), artemether-lumefantrine (AL), or chlorproguanil-dapsone-artesunate (CD+A). Overall, 4,116 children 6-59 mo old with uncomplicated Plasmodium falciparum malaria were treated (1,226 with AL, 1,002 with ASAQ, 413 with CD+A, and 1,475 with DHAPQ), actively followed up until day 28, and then passively followed up for the next 6 mo. At day 28, for the PCR-adjusted efficacy, non-inferiority was established for three pair-wise comparisons: DHAPQ (97.3%) versus AL (95.5%) (odds ratio [OR]: 0.59, 95% CI: 0.37-0.94); DHAPQ (97.6%) versus ASAQ (96.8%) (OR: 0.74, 95% CI: 0.41-1.34), and ASAQ (97.1%) versus AL (94.4%) (OR: 0.50, 95% CI: 0.28-0.92). For the PCR-unadjusted efficacy, AL was significantly less efficacious than DHAPQ (72.7% versus 89.5%) (OR: 0.27, 95% CI: 0.21-0.34) and ASAQ (66.2% versus 80.4%) (OR: 0.40, 95% CI: 0.30-0.53), while DHAPQ (92.2%) had higher efficacy than ASAQ (80.8%) but non-inferiority could not be excluded (OR: 0.35, 95% CI: 0.26-0.48). CD+A was significantly less efficacious than the other three treatments. Day 63 results were similar to those observed at day 28.
  
  
  CONCLUSIONS
  This large head-to-head comparison of most currently available ACTs in sub-Saharan Africa showed that AL, ASAQ, and DHAPQ had excellent efficacy, up to day 63 post-treatment. The risk of recurrent infections was significantly lower for DHAPQ, followed by ASAQ and then AL, supporting the recent recommendation of considering DHAPQ as a valid option for the treatment of uncomplicated P. falciparum malaria.
  
  
  BACKGROUND
  ClinicalTrials.gov NCT00393679; Pan African Clinical Trials Registry PACTR2009010000911750
mesh_terms: D000328:Adult; D017954:Africa South of the Sahara; D000655:Amodiaquine / Q000627:therapeutic use; D000962:Antimalarials / Q000627:therapeutic use*; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins / Q000627:therapeutic use; D004338:Drug Combinations; D004983:Ethanolamines / Q000627:therapeutic use; D005260:Female; D005449:Fluorenes / Q000627:therapeutic use; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male
chemical_list: D000962:Antimalarials; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes; C515299:amodiaquine, artesunate drug combination; D000655:Amodiaquine; C039060:artenimol
references.citation: Lancet. 2010 Aug 28;376(9742):739-41
references.pmid: 20599264
references.citation: J Infect Dis. 2006 Apr 15;193(8):1151-9
references.pmid: 16544256
references.citation: Malar J. 2008 Nov 18;7:237
references.pmid: 19017387
references.citation: PLoS One. 2009 Dec 22;4(12):e8410
references.pmid: 20027314
references.citation: Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):193-7
references.pmid: 18165492
references.citation: Am J Trop Med Hyg. 2006 Jun;74(6):986-90
references.pmid: 16760508
references.citation: PLoS One. 2007 Oct 31;2(10):e1101
references.pmid: 17971864
references.citation: PLoS Med. 2007 Nov 6;4(11):e309
references.pmid: 17988171
references.citation: Lancet. 2010 Apr 24;375(9724):1457-67
references.pmid: 20417857
references.citation: Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):181-92
references.pmid: 18165491
references.citation: Br J Clin Pharmacol. 2006 Mar;61(3):289-300
references.pmid: 16487222
references.citation: Lancet. 2006 Jun 24;367(9528):2075-85
references.pmid: 16798391
references.citation: PLoS One. 2010 Jul 30;5(7):e11759
references.pmid: 20689585
references.citation: PLoS One. 2009 Aug 19;4(8):e6682
references.pmid: 19690618
references.citation: Stat Med. 2000 Jul 15;19(13):1707-28
references.pmid: 10861773
references.citation: Clin Infect Dis. 2009 Dec 1;49(11):1629-37
references.pmid: 19877969
references.citation: PLoS One. 2009 Nov 17;4(11):e7871
references.pmid: 19936217
references.citation: Lancet. 2007 Mar 3;369(9563):757-765
references.pmid: 17336652
references.citation: Am J Trop Med Hyg. 2006 Aug;75(2):219-25
references.pmid: 16896122
references.citation: Malar J. 2009 Jun 08;8:125
references.pmid: 19505304
references.citation: Trop Med Int Health. 2010 May;15(5):608-13
references.pmid: 20214761
references.citation: Lancet. 2005 Apr 23-29;365(9469):1474-80
references.pmid: 15850631
references.citation: Lancet Infect Dis. 2010 Aug;10(8):545-55
references.pmid: 20637696
references.citation: Antimicrob Agents Chemother. 2008 May;52(5):1589-96
references.pmid: 18299409
references.citation: Lancet. 2007 Sep 22;370(9592):1035-9
references.pmid: 17889242
references.citation: Trans R Soc Trop Med Hyg. 2002 Nov-Dec;96(6):660-3
references.pmid: 12625146
references.citation: Stat Med. 1998 Apr 30;17(8):873-90
references.pmid: 9595617
references.citation: PLoS One. 2010 Jul 30;5(7):e11880
references.pmid: 20689583
references.citation: Lancet Infect Dis. 2010 Jun;10(6):405-16
references.pmid: 20510281
references.citation: Malar J. 2006 Apr 24;5:33
references.pmid: 16635265
references.citation: Am J Trop Med Hyg. 1995 Jun;52(6):565-8
references.pmid: 7611566
references.citation: Trop Med Int Health. 2004 Feb;9(2):200-8
references.pmid: 15040556
references.citation: Trans R Soc Trop Med Hyg. 2000 Apr;94 Suppl 1:S1-90
references.pmid: 11103309
references.citation: Am J Trop Med Hyg. 1998 May;58(5):619-24
references.pmid: 9598451
references.citation: Am J Trop Med Hyg. 2007 Jan;76(1):42-7
references.pmid: 17255227
references.citation: Cent Afr J Med. 1996 Apr;42(4):109-11
references.pmid: 8791866
references.citation: Trans R Soc Trop Med Hyg. 2002 May-Jun;96(3):310-7
references.pmid: 12174786
references.citation: Lancet Infect Dis. 2010 Oct;10(10):673-81
references.pmid: 20832366
references.citation: Trends Parasitol. 2006 Jul;22(7):301-7
references.pmid: 16757213
references.citation: Bull Soc Pathol Exot. 2006 Jul;99(3):161-5
references.pmid: 16983817
references.citation: Expert Opin Pharmacother. 2009 Jun;10(8):1291-306
references.pmid: 19463069
references.citation: Malar J. 2008 Jul 09;7:125
references.pmid: 18613962
references.citation: Trans R Soc Trop Med Hyg. 2002 Mar-Apr;96(2):199-201
references.pmid: 12055815
references.citation: JAMA. 2007 May 23;297(20):2210-9
references.pmid: 17519410
references.citation: Malar J. 2007 May 02;6:52
references.pmid: 17474975
references.citation: Lancet. 2004 Oct 16-22;364(9443):1411-20
references.pmid: 15488216
references.citation: Antimicrob Agents Chemother. 2010 May;54(5):1762-8
references.pmid: 20194698
references.citation: Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):170-80
references.pmid: 18165490
references.citation: Antimicrob Agents Chemother. 2004 Nov;48(11):4271-80
references.pmid: 15504852